Literature DB >> 23024367

The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells.

Rongyang Dai1, Juanjuan Li, Jing Fu, Yao Chen, Ruoyu Wang, Xiaofang Zhao, Tao Luo, Junjie Zhu, Yibin Ren, Jie Cao, Youwen Qian, Ning Li, Hongyang Wang.   

Abstract

Pro-tumorigenic function of the p38 kinase plays a critical role in human cholangiocarcinogenesis. However, the underlying mechanism remains incompletely understood. Here, we report that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), contributes to the pro-tumorigenic ability of p38 in human cholangiocarcinoma cells. Both p38 and c-Met promote the proliferation and invasion of human cholangiocarcinoma cells. Importantly, inhibition or knockdown of p38 decreased the basal activation of c-Met. Tyrosine phosphatase inhibitor studies revealed that p38 promotes the activity of c-Met, at least in part, by inhibiting dephosphorylation of the receptor. Moreover, density enhanced phosphatase-1 (DEP-1) is involved in p38-mediated inhibiting dephosphorylation of c-Met. Furthermore, p38 inhibits the degradation of c-Met. Taken together, these data provide a potential mechanism to explain how p38 promotes human cholangiocarcinoma cell proliferation and invasion. We propose that the link between p38 and c-Met is implicated in the progression of human cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024367      PMCID: PMC3501014          DOI: 10.1074/jbc.M112.406520

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Biliary tract cancers.

Authors:  J Figueras; C Valls; E Jaurrieta
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  The p38 signal transduction pathway: activation and function.

Authors:  K Ono; J Han
Journal:  Cell Signal       Date:  2000-01       Impact factor: 4.315

3.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

Authors:  P Peschard; T M Fournier; L Lamorte; M A Naujokas; H Band; W Y Langdon; M Park
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

4.  c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

Authors:  Hanning You; Wei Ding; Hien Dang; Yixing Jiang; C Bart Rountree
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

5.  Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.

Authors:  J Park; L Tadlock; G J Gores; T Patel
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

6.  Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.

Authors:  Deepika Arora; Sabine Stopp; Sylvia-Annette Böhmer; Julia Schons; Rinesh Godfrey; Kristina Masson; Elena Razumovskaya; Lars Rönnstrand; Simone Tänzer; Reinhard Bauer; Frank-D Böhmer; Jörg P Müller
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

7.  Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells.

Authors:  Takahiko Kogai; Yan-Yun Liu; Kaizeen Mody; Deborah V Shamsian; Gregory A Brent
Journal:  J Biol Chem       Date:  2011-12-08       Impact factor: 5.157

8.  Disturbance of Ca2+ homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells.

Authors:  Rongyang Dai; Juanjuan Li; Jing Fu; Yao Chen; Lexing Yu; Xiaofang Zhao; Youwen Qian; Huilu Zhang; Haiyang Chen; Yibin Ren; Bo Su; Tao Luo; Junjie Zhu; Hongyang Wang
Journal:  J Biol Chem       Date:  2012-03-14       Impact factor: 5.157

9.  Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line.

Authors:  L Tadlock; T Patel
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

Review 10.  Cancer therapy: can the challenge be MET?

Authors:  Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Trends Mol Med       Date:  2005-06       Impact factor: 11.951

View more
  9 in total

1.  Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.

Authors:  Sumalee Obchoei; Kanlayanee Sawanyawisuth; Chaisiri Wongkham; Watchara Kasinrerk; Qizhi Yao; Changyi Chen; Sopit Wongkham
Journal:  Tumour Biol       Date:  2014-10-10

2.  Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal‑regulated kinase signaling pathway.

Authors:  Thitinee Vanichapol; Kawin Leelawat; Suradej Hongeng
Journal:  Mol Med Rep       Date:  2015-05-27       Impact factor: 2.952

3.  Implication of transcriptional repression in compound C-induced apoptosis in cancer cells.

Authors:  R Y Dai; X F Zhao; J J Li; R Chen; Z L Luo; L X Yu; S K Chen; C Y Zhang; C Y Duan; Y P Liu; C H Feng; X M Xia; H Li; J Fu; H Y Wang
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

4.  Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population.

Authors:  N Trachu; E Sirachainan; N Larbcharoensub; W Rattanadech; S Detarkom; N Monnamo; K Kamprerasart; D MunTham; C Sukasem; T Reungwetwattana
Journal:  Onco Targets Ther       Date:  2017-10-11       Impact factor: 4.147

5.  Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.

Authors:  Sunbin Ling; Haiyang Xie; Fan Yang; Qiaonan Shan; Haojiang Dai; Jianyong Zhuo; Xuyong Wei; Penghong Song; Lin Zhou; Xiao Xu; Shusen Zheng
Journal:  J Hematol Oncol       Date:  2017-02-28       Impact factor: 17.388

6.  Mutational spectrum and precision oncology for biliary tract carcinoma.

Authors:  Jianzhen Lin; Yinghao Cao; Xu Yang; Guangyu Li; Yang Shi; Dongxu Wang; Junyu Long; Yang Song; Jinzhu Mao; Fucun Xie; Yi Bai; Lei Zhang; Xiaobo Yang; Xueshuai Wan; Anqiang Wang; Mei Guan; Lin Zhao; Ke Hu; Jie Pan; Li Huo; Xin Lu; Yilei Mao; Xinting Sang; Henghui Zhang; Kai Wang; Xiaoyue Wang; Haitao Zhao
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

7.  JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction.

Authors:  Chunhong Feng; Kai He; Chunyan Zhang; Song Su; Bo Li; Yuxiao Li; Chun-Yan Duan; Shaokun Chen; Run Chen; Youping Liu; Hong Li; Mei Wei; Xianming Xia; Rongyang Dai
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

8.  MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1.

Authors:  Xianglai Xu; Shiqi Li; Yiwei Lin; Hong Chen; Zhenghui Hu; Yeqing Mao; Xin Xu; Jian Wu; Yi Zhu; Xiangyi Zheng; Jindan Luo; Liping Xie
Journal:  J Transl Med       Date:  2013-11-02       Impact factor: 5.531

Review 9.  Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link.

Authors:  Chaobo Chen; Leonard J Nelson; Matías A Ávila; Francisco Javier Cubero
Journal:  Cells       Date:  2019-09-28       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.